As AstraZeneca’s share price drops 11%, does the stock look an unmissable bargain to me?

AstraZeneca’s share price has fallen 11%, leaving it looking even more of a bargain to me than before, supported by strong earnings growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Arrow symbol glowing amid black arrow symbols on black background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca’s (LSE: AZN) share price is down 11% from its 3 September 12-month traded high of £133.38.

Such a drop raises the question to me of whether a bargain is to be had here.

Are the shares undervalued?

My starting point in ascertaining whether the shares are underpriced is to look at key stock valuation measures.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

On the first of these — the price-to-earnings ratio (P/E) — AstraZeneca is bottom of the list of its competitors. It trades at a P/E of just 37.6 compared to an average of 64.6 for its peers. So it looks very cheap on this basis.

The same is true of the price-to-book ratio (P/B) ratio. It is again bottom of its competitor group at a P/B of only 6.1 against an average of 37.3.

And the same applies to the price-to-sales ratio (P/S) too. AstraZeneca shares are presently at 4.9 against a competitor average of 13.2.

To translate these undervaluations into cash terms, I ran a discounted cash flow analysis using other analysts’ figures and my own.

This shows AstraZeneca shares are 55% underpriced at their current £119.35 level. So a fair value for the stock would be £265.22.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL21 Oct 201921 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

It could go lower or higher than that, of course, given the unpredictability of the market. However, it underlines to me how big a bargain the shares look right now.

And the growth prospects?

Ultimately, a company’s share price and dividends are driven by earnings. A risk to AstraZeneca’s is a serious failure in any of its major product lines, as this could prove costly to remedy. It could also damage its reputation.

However, its H1 2024 results showed total revenue up 18% from H1 2023 to $25.617bn. Consequently, full-year 2024 guidance for the figure was raised to mid-teens percent from low double-digit to low-teens.

Analysts forecast that AstraZeneca’s earnings will grow by 16.4% every year to end-2026. Revenue is the total money a business receives, while earnings refers to the remaining money after expenses.

Beyond that, the firm expects $80bn+ in revenues by 2030, against $45.8bn at the end of 2023.

Where will the growth come from?

AstraZeneca has 189 new drugs at various stages of development in its pipeline. By comparison, its leading UK peer GSK has just 71.

And barely a week goes by without a positive announcement related to one of its product lines. October has been no exception. Mid-month saw its Enhertu breast cancer treatment drug gain approval in the huge Chinese market.

Earlier in the month it signed a $1.92bn deal with CSPC to access the Hong Kong firm’s extensive cardiovascular drugs pipeline. This includes the development of ground-breaking lipoprotein work that could benefit patients with high levels of the ‘bad cholesterol’ LDL.

And just before that came the granting of a priority review in the US for the rollout of its Calquence cancer drug.

My investment view

I already own shares in AstraZeneca, based on the firm’s strong earnings growth prospects. These should power its share price and dividend higher in the coming years, in my view.

Given this, I see the recent share price fall as an unmissable bargain opportunity, and I will buy more stock soon.

Should you buy AstraZeneca now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »